3SOF

Memory Pharmaceuticals Announces Collaboration to Develop PDE10 Inhibitors for Central Nervous System Disorders with Amgen
Monday October 17, 7:00 am ET


MONTVALE, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that it has entered into an exclusive worldwide collaboration and license agreement with Amgen to develop PDE10 inhibitors as human therapeutics, including as a potential treatment for certain neurological and psychiatric disorders. The collaboration will focus on the optimization of lead compounds that the Company has identified and that have demonstrated effectiveness in the selective inhibition of PDE10 activity in several animal models.
Under the collaboration, Memory Pharmaceuticals will receive an upfront payment of $5.0 million, and the Company could also receive significant milestone payments for the successful achievement of research, development, approval and sales events for compounds that progress under the collaboration. In addition, Memory Pharmaceuticals is eligible to receive royalties that will increase with increasing sales levels on worldwide sales of marketed products from the collaboration. Over the next two years of the collaboration, Memory Pharmaceuticals could receive research funding of $5.1 million.

"PDE10 is a very compelling target for treating certain central nervous system disorders, and we are delighted to have Amgen as a partner in our effort to aggressively pursue this target and address the pervasive unmet needs of patients with these disorders," said Jim Sulat, President and Chief Executive Officer of Memory Pharmaceuticals. "In addition, we believe this collaboration is further validation of Memory Pharmaceuticals' solid discovery capabilities."

PDE10 is a class of phosphodiesterases that degrades cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10 activity, levels of cAMP and cGMP are increased within neurons, and the ability of these neurons to function properly is thereby improved. PDE10 has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression, vascular dementia, mild cognitive impairment, Parkinson's disease and memory impairments associated with aging. For additional information, please visit our website at http://www.memorypharma.com.

good news for MEMY:
Memory Pharmaceuticals Announces Collaboration to Develop PDE10 Inhibitors for Central Nervous System Disorders with Amgen
Monday October 17, 7:00 am ET

MONTVALE, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that it has entered into an exclusive worldwide collaboration and license agreement with Amgen to develop PDE10 inhibitors as human therapeutics, including as a potential treatment for certain neurological and psychiatric disorders. The collaboration will focus on the optimization of lead compounds that the Company has identified and that have demonstrated effectiveness in the selective inhibition of PDE10 activity in several animal models.
Under the collaboration, Memory Pharmaceuticals will receive an upfront payment of $5.0 million, and the Company could also receive significant milestone payments for the successful achievement of research, development, approval and sales events for compounds that progress under the collaboration. In addition, Memory Pharmaceuticals is eligible to receive royalties that will increase with increasing sales levels on worldwide sales of marketed products from the collaboration. Over the next two years of the collaboration, Memory Pharmaceuticals could receive research funding of $5.1 million.
"PDE10 is a very compelling target for treating certain central nervous system disorders, and we are delighted to have Amgen as a partner in our effort to aggressively pursue this target and address the pervasive unmet needs of patients with these disorders," said Jim Sulat, President and Chief Executive Officer of Memory Pharmaceuticals. "In addition, we believe this collaboration is further validation of Memory Pharmaceuticals' solid discovery capabilities."

PDE10 is a class of phosphodiesterases that degrades cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10 activity, levels of cAMP and cGMP are increased within neurons, and the ability of these neurons to function properly is thereby improved. PDE10 has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders.

please use search functionality before posting:

http://www.3stocksonfire.org/trading/index.php?topic=2882.new#new

Signs of life in the pre-market. If it stays this direction for today!
+21.77%....Volume  @ 14,600

this stock was up to 3.30 in pre-market, back down a little under $3 now; but I think the news was fanatastic and this should move this stock up a  lot higher this week...

Collaboration with Amgen is big news and the upfront $5 million payment is great! Royalties too.

After a little accumulation this stock should pop back up.

 Memory Pharmaceuticals to Present at BIO InvestorForum 2005[/glow]

MONTVALE, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that Jim Sulat, President and Chief Executive Officer, will provide a Company update at the BIO InvestorForum 2005 on October 19th at 10:40 a.m. PDT, at the Palace Hotel in San Francisco.

Interested parties may access a live audio webcast of the presentation by visiting the Investor Relations section of Memory Pharmaceuticals' website at http://www.memorypharma.com. An archived version of the webcast will be available at the same location through October 25, 2005.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression, vascular dementia, mild cognitive impairment, Parkinson's disease and memory impairments associated with aging. For additional information, please visit our website at http://www.memorypharma.com.

SOURCE  Memory Pharmaceuticals Corp.
    -0-                             10/12/2005
    /CONTACT:  Jzaneen Lalani, Vice President, Legal Affairs of Memory
Pharmaceuticals Corp., +1-201-802-7140; or Laura Perry of Stern Investor
Relations, Inc. for Memory Pharmaceuticals Corp., +1-212-362-1200/
    /Web site:  http://www.memorypharma.com /
    (MEMY)

CO:  Memory Pharmaceuticals Corp.
ST:  New Jersey
IN:  BIO HEA MTC
SU:  CCA TDS

JC
-- NYW006 --
1931 10/12/2005 07:30 EDT http://www.prnewswire.com

(NASDAQ:MEMY) Is TheSUBWAY.com's Pick of the Day. Last Pick Traded Up 6% Intraday...

Filled Gap at 2.71... ready to rock...

Thanks Setravis, Amarens and Stocky for the applause....sorry didnt read this thread for awhile until now.

Got a little spooky there with the pullback...glad to see it moving up for all holders.

Good luck guys!

julia

pullback today was to fill the gap that was made in the morning with that big black oxy candle... believe me you want that filled.

Tomorrow we should continue up. there is an event on Wednesday that should provide some more info on MEMY.

Hope for you all it will continue. I took my profits. Was happy with 30%  .

Good luck to all holding

Amarens

I see today that the stock is at former support and so far has an NR7 so may move up tomorrow - or may tank

http://tinyurl.com/bny4a

link is not working metro:
Not Found

The requested URL /MEMY I see is back to a former support and right now canlde is a NR7 so maybe boucne tomorrow - worth watching - could tank also http://stockcharts.com/def/servlet/SC.web was not found on this server.
Apache/2.0.46 (Red Hat) Server at forwarding.tinyurl.com Port 80

could you please post again?

thanks
Oliver

Hey there just want to get some chatter goin about MEMY , Im still Long and Strong bought back in on the dips, With this much Insider buying, low float, deals with Amgen, aging baby boomers, and phase II testing updates on the way This is the biggest position in my portfolio.

Might take some time but I feel that there's strong support here around $2

this is in a trading channel of $2.10 - $2.50...  will keep in this channel until we get some news.  Then it will pop to over $3... 

Quote from: lbotez on November 13, 2005, 11:32:18 PM
this is in a trading channel of $2.10 - $2.50...  will keep in this channel until we get some news.  Then it will pop to over $3... 

Ibotez, you may be right but I see more of a symmetrical triangle here.  At today's price, MEMY represents a great risk/reward trade if you buy at the ascending trendline and either use that TL or the most recent low of $2.06 as a stop.